Companies
Novigenix
runs an AI-powered blood-transcriptomic platform with published results on early colorectal-cancer detection, and recently secured funding (EUR 1.8 million) to scale its precision-oncology platform and spun out an AI-focused unit to accelerate its immune-intelligence technology.
- Country
- Switzerland
Growth
AI blood-transcriptomic platform
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | EUR 1.8 million awarded through the BRECISE IHI grant (2025) | ggba.swiss · novigenix.com |
| Certification | ISO 13485 certified | novigenix.com |
| Regulatory approval | Received regulatory approval for COLOX in 2014 | novigenix.com |
| Headcount | 18 employees | novigenix.com |
| Revenue | USD 114 million annual revenue medium confidence | novigenix.com |
| Production site | Route de la Corniche 3, 1066 Epalinges, Switzerland | northdata.com |
Independent sources: ggba.swiss · northdata.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Multi-cancer early detection (MCED) | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.